Recruitment

Recruitment Status
Unknown status
Estimated Enrollment
Same as current

Summary

Conditions
Nocturnal Enuresis
Type
Interventional
Phase
Phase 4
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

We will prospectively assess the utilization of Desmopressin in improving nocturnal enuresis in patients after radical cystectomy with orthotopic bladder reconstruction. Patients after radical cystectomy with neobladder reconstruction will be given Desmopressin 0.1 mg once a day for a duration of on...

We will prospectively assess the utilization of Desmopressin in improving nocturnal enuresis in patients after radical cystectomy with orthotopic bladder reconstruction. Patients after radical cystectomy with neobladder reconstruction will be given Desmopressin 0.1 mg once a day for a duration of one month. Before beginning treatment patients will be given the NNES-Q questionnaire to assess severity of nocturnal enuresis. At the end of treatment, the same questionnaire will be given to all patients to assess if nocturnal enuresis improved. Sodium levels will be tested before treatment, 2 weeks after beginning treatment and at the end of treatment.

Tracking Information

NCT #
NCT01582542
Collaborators
Not Provided
Investigators
Principal Investigator: Ofer Yossepowitch, MD Rabin Medical Center